Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2013, Article ID 542646, 4 pages
http://dx.doi.org/10.1155/2013/542646
Review Article

Global Cardiovascular Risk Assessment in the Management of Primary Hypertension: The Role of the Kidney

Università Degli Studi e I.R.C.C.S. Azienda Ospedaliera Universitaria San Martino-IST, Istituto Nazionale per la Ricerca sul Cancro, 16125 Genoa, Italy

Received 20 May 2013; Accepted 8 July 2013

Academic Editor: B. Waeber

Copyright © 2013 Francesca Viazzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Ezzati, A. D. Lopez, A. Rodgers, S. Vander Hoorn, and C. J. L. Murray, “Selected major risk factors and global and regional burden of disease,” Lancet, vol. 360, no. 9343, pp. 1347–1360, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Mancia, R. Fagard, K. Narkiewicz et al., “2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC),” Journal of Hypertension, vol. 31, pp. 1281–1357, 2013. View at Google Scholar
  3. L. G. Ogden, J. He, E. Lydick, and P. K. Whelton, “Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification,” Hypertension, vol. 35, no. 2, pp. 539–543, 2000. View at Google Scholar · View at Scopus
  4. G. Leoncini, G. Sacchi, F. Viazzi et al., “Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach,” Journal of Hypertension, vol. 20, no. 7, pp. 1315–1321, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. R. B. Devereux and M. H. Alderman, “Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events,” Circulation, vol. 88, no. 4 I, pp. 1444–1455, 1993. View at Google Scholar · View at Scopus
  6. J. K. Ghali, Y. Liao, and R. S. Cooper, “Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease,” Journal of the American College of Cardiology, vol. 31, no. 7, pp. 1635–1640, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. D. H. O'Leary, J. F. Polak, R. A. Kronmal, T. A. Manolio, G. L. Burke, and S. K. Wolfson Jr., “Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults,” New England Journal of Medicine, vol. 340, no. 1, pp. 14–22, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Viazzi, G. Leoncini, D. Parodi et al., “Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension,” Journal of the American Society of Nephrology, vol. 16, no. 3, supplement, pp. S89–S91, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Matsushita, M. van der Velde, B. C. Astor et al., “Association of eGFR and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis,” Lancet, vol. 375, pp. 2073–2081, 2010. View at Google Scholar
  10. P. Verdecchia, G. Schillaci, C. Borgioni et al., “Prognostic significance of serial changes in left ventricular mass in essential hypertension,” Circulation, vol. 97, no. 1, pp. 48–54, 1998. View at Google Scholar · View at Scopus
  11. R. E. Schmieder, M. P. Schlaich, A. U. Klingbeil, and P. Martus, “Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996),” Nephrology Dialysis Transplantation, vol. 13, no. 3, pp. 564–569, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Dahlöf, R. B. Devereux, S. E. Kjeldsen et al., “Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol,” Lancet, vol. 359, no. 9311, pp. 995–1003, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. N. O. Borhani, M. Mercuri, P. A. Borhani et al., “Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial,” Journal of the American Medical Association, vol. 276, no. 10, pp. 785–791, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Zanchetti, E. Agabiti Rosei, C. Dal Palù, G. Leonetti, B. Magnani, and A. Pessina, “The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness,” Journal of Hypertension, vol. 16, no. 11, pp. 1667–1676, 1998. View at Google Scholar · View at Scopus
  15. A. Simon, J. Gariépy, D. Moyse, and J. Levenson, “Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes,” Circulation, vol. 103, no. 24, pp. 2949–2954, 2001. View at Google Scholar · View at Scopus
  16. A. Zanchetti, M. G. Bond, M. Hennig et al., “Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial,” Circulation, vol. 106, no. 19, pp. 2422–2427, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Turnbull, “Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials,” Lancet, vol. 362, no. 9395, pp. 1527–1535, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Pontremoli, “Microalbuminuria in essential hypertension—its relation to cardiovascular risk factors,” Nephrology Dialysis Transplantation, vol. 11, no. 11, pp. 2113–2115, 1996. View at Google Scholar · View at Scopus
  19. R. Pontremoli, M. Ravera, G. P. Bezante et al., “Left ventricular geometry and function in patients with essential hypertension and microalbuminuria,” Journal of Hypertension, vol. 17, no. 7, pp. 993–1000, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. J. S. Jensen, B. Feldt-Rasmussen, S. Strandgaard, M. Schroll, and K. Borch-Johnsen, “Arterial hypertension, microalbuminuria, and risk of ischemic heart disease,” Hypertension, vol. 35, no. 4, pp. 898–903, 2000. View at Google Scholar · View at Scopus
  21. M. H. Olsen, K. Wachtell, K. Borch-Johnsen et al., “A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE study,” Journal of Human Hypertension, vol. 16, no. 8, pp. 591–595, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Wachtell, H. Ibsen, M. H. Olsen et al., “Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study,” Annals of Internal Medicine, vol. 139, no. 11, pp. 901–906, 2003. View at Google Scholar · View at Scopus
  23. H. Ibsen, M. H. Olsen, K. Wachtell et al., “Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study,” Hypertension, vol. 45, no. 2, pp. 198–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. E. Schmieder, J. F. E. Mann, H. Schumacher et al., “Changes in albuminuria predict mortality and morbidity in patients with vascular disease,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1353–1364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Viazzi, G. Leoncini, N. Conti et al., “Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients,” Journal of Hypertension, vol. 28, no. 4, pp. 848–855, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Leoncini, E. Ratto, F. Viazzi et al., “Global risk stratification in primary hypertension: the role of the kidney,” Journal of Hypertension, vol. 26, no. 3, pp. 427–432, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. S. Levey, J. Coresh, E. Balk et al., “National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, Classification, and Stratification,” Annals of Internal Medicine, vol. 139, no. 2, pp. 137–I36, 2003. View at Google Scholar · View at Scopus
  29. H. Haller, J. Menne, and G. Mancia, “Awareness and behaviour of European physicians in relation to microalbuminuria and organ damage: an ESH-endorsed survey,” Journal of Hypertension, vol. 28, no. 11, pp. 2204–2209, 2010. View at Publisher · View at Google Scholar · View at Scopus